Dr Simon Hart

Study of the lung endothelium in idiopathic pulmonary fibrosis Sep 1, 2020 - Sep 30, 2023

A cell model for discovering biomarkers and druggable targets for pulmonary fibrosis May 1, 2023 - Nov 30, 2024

Updating (Reviewing and Printing) the Patient's Guide to Pulmonary Fibrosis. Nov 1, 2022 - Oct 31, 2023
This is an annual follow up/annual review for the Project 3632727: Development And Publication Of The Booklet For The Pulmonary Fibrosis (disease With A Degree Of Similarity To Coronavirus Disease).


Chronic diseases associated... Read More about Updating (Reviewing and Printing) the Patient's Guide to Pulmonary Fibrosis..

Development and publication of the booklet for the pulmonary fibrosis (disease with a degree of similarity to coronavirus disease). Nov 1, 2020 - Oct 31, 2021
Chronic diseases associated with fibrosis present a challenge for healthcare; two of them are idiopathic pulmonary fibrosis (IPF) and lymphoedema. IPF is a form of lung disease in which scarring occurs (with no known cause) leading to increased breat... Read More about Development and publication of the booklet for the pulmonary fibrosis (disease with a degree of similarity to coronavirus disease)..

An exploratory sub-study to protocol GLPG1690-CL-303 to assess lung function in patients with idiopathic pulmonary fibrosis, using hyperpolarized xenon magnetic resonance imaging Nov 1, 2019 - Apr 30, 2022

TR12: A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis with Nalbuphine ER Tablets for the Treatment of Cough Oct 1, 2019 - Dec 31, 2022

ATLAS: A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis Jun 1, 2019 - Jan 31, 2022

SCENIC: Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) May 1, 2019 - Jan 31, 2022

ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebocontrolled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. Aug 1, 2019 - Dec 31, 2022

A single arm, open-label exploratory clinical trial of azithromycin in pulmonary sarcoidosis Mar 1, 2019 - Sep 30, 2020